Human meibum and tear film derived cholesteryl and wax esters in meibomian gland dysfunction and tear film structure

PurposeThis study evaluated the presence and roles of cholesteryl esters (CEs) and wax esters (WEs) from human tear film and meibum in meibomian gland dysfunction (MGD).MethodsOut of 195 enrolled subjects, 164 and 179 subjects provided tear and meibum samples, respectively. Subjects were classified into normal, asymptomatic MGD, MGD, and mixed (MGD & aqueous deficient). The precorneal tear film (PCTF) thinning rate (evaporation) was measured using optical coherence tomography. Lipids extracted from tear and meibum samples were infused into a SCIEX 5600 TripleTOF mass spectrometer. CE and WE intensities quantified with Analyst 1.7 TF and LipidView 1.3 were compared across disease groups in MetaboAnalyst 5.0 and correlated with PCTF thinning rates.ResultsThe numbers of unique CEs and WEs identified in the samples were 125 and 86, respectively. Unsupervised Principal Component (PC) analysis and supervised Partial Least Square Discriminant analysis exhibited little separation among groups for both CEs and WEs in tears and meibum. Spearman's correlation analyses showed no association between either the first or second PC scores with PCTF thinning rates.ConclusionThe abundances of human PCTF and meibum-derived CEs and WEs were independent of MGD disease status and PCTF thinning (evaporation). CEs and WEs alterations do not contribute to alterations in tear film dynamics in MGD, such as has been demonstrated by the (O-acyl) ω-hydroxy fatty acids (OAHFAs).     

Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes

Purpose

To evaluate the effect of 3% diquafosol ophthalmic solution on tear film lipid layer thickness (LLT) in normal human eyes by tear interferometry.

Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting

Meibomian gland dysfunction (MGD) is a common and chronic disorder that has a significant adverse impact on patients' quality of life. It is a leading cause of evaporative dry eye disease (DED), as meibomian glands play an important role in providing lipids to the tear film, which helps to retard the evaporation of tears from the ocular surface. MGD is also often present in conjunction with primary aqueous-deficient DED. Obstructive MGD, the most commonly observed type of MGD, is the main focus of this article. MGD is probably caused by a combination of separate conditions: primary obstructive hyperkeratinization of the meibomian gland, abnormal meibomian gland secretion, eyelid inflammation, corneal inflammation and damage, microbiological changes, and DED. Furthermore, skin diseases such as rosacea may play a part in its pathology. Accurate diagnosis is challenging, as it is difficult to differentiate between ocular surface diseases, but is crucial when choosing treatment options. Ocular imaging has advanced in recent years, providing ophthalmologists with a better understanding of ocular diseases. This review presents a literature update on the 2011 MGD workshop and an optimized approach to accurate diagnosis of MGD using currently available methods and tests. It also outlines the emerging technologies of interferometry, non-contact meibography, keratography and in vivo confocal laser microscopy, which offer exciting possibilities for the future. Selected treatment options for MGD are also discussed.     

Human meibum and tear film derived (O-acyl)-omega-hydroxy fatty acids in meibomian gland dysfunction

PurposeThe molecular basis of the tear film and lipid layer alterations in meibomian gland dysfunction (MGD) is unknown. This study aimed to identify and compare (O-acyl)-omega-hydroxy fatty acids (OAHFAs) derived from human meibum and tears in MGD.MethodsOf 195 eligible subjects (18–84 years, 62.6% female), 183 and 174 provided samples for tears and meibum, respectively. Subjects were classified into four groups: Normal, Asymptomatic MGD, MGD, and Mixed. Samples from the right eye of each subject were infused into the SCIEX 5600 TripleTOF mass spectrometer in negative ion mode. Lipid intensities identified with Analyst1.7 TF and SCIEX LipidView1.3 were normalized by an internal standard and total ion current, then statistically compared in MetaboAnalyst 4.0.ResultsIn meibum and tears, 76 and 78 unique OAHFAs were identified, respectively. The five most frequent and abundant OAHFAs were 18:2/16:2, 18:1/32:1, 18:1/30:1, 18:2/32:1, and 18:1/34:1. Two OAHFAs, 18:2/20:2 and 18:2/20:1, were identified only in tears. Initial univariate analysis revealed three differently regulated OAHFAs in meibum and eight in tears. Partial Least Square Discriminant Analysis showed 18:1/32:1, 18:2/16:2, 18:1/34:1 and 18:0/32:1 in tears, and 18:2/16:2, 18:1/32:1 and 18:2/32:2 in meibum, had variable importance in projection scores >1.5 and contributed the most to the separation of groups. In both meibum and tears, all OAHFAS except 18:2/16:2 were reduced in MGD compared to the normal group.ConclusionMGD is accompanied by differential expression of specific OAHFAs in meibum and tears. These results suggest OAHFAs play a role in the altered biochemical profile of the tear film lipid layer in humans with MGD.     

睑板腺功能障碍研究进展

睑板腺功能障碍(meibomian gland dysfunction,MGD)以睑板腺终末导管阻塞和睑板腺分泌物的质量或数量改变为特征.睑板腺分泌的脂质成分发生相应改变,造成泪膜的稳定性下降和泪液蒸发量增加,从而导致干眼发生.目前MGD的发病原因尚不明确,临床上采取的治疗往往是对症治疗.本文主要对MGD的泪膜脂质变化及其国内外诊治进展进行总结.     

睑板腺功能障碍药物治疗研究进展北大核心CSCD

睑板腺功能障碍(MGD)是一种慢性、弥漫性睑板腺异常,其病因众多,发病机制复杂且患病率高,已经成为临床上常见的眼表疾病之一。MGD的治疗是近年来临床研究的热点和难点,主要包括改善生活方式、物理治疗、药物治疗、手术治疗,其中药物治疗占重要地位。按照作用机制可将治疗MGD的药物大致分为3大类:第1类是改善泪液质量和泪膜稳定性的药物,包括人工泪液和眼表润滑剂、促泌剂(促进脂质、水液以及黏蛋白分泌)和雄激素等;第2类是改善眼表微环境的药物,包括局部及全身应用抗生素、糖皮质激素类滴眼液、非甾体类抗炎药、免疫抑制剂、除螨药物等;第3类是营养补充剂和神经保护剂,包括维生素D3、ω-3脂肪酸、自体血清等。本文就目前临床常用及研究较多的MGD治疗药物进行综述,为MGD临床治疗和研究提供参考。     

Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction

PurposeTo assess long-term cumulative treatment effects of intense pulsed light (IPL) therapy in meibomian gland dysfunction (MGD).MethodsEighty-seven symptomatic participants (58 female, mean ± SD age, 53 ± 16 years) with clinical signs of MGD were enrolled in a prospective, double-masked, parallel-group, randomised, placebo-controlled trial. Participants were randomised to receive either four or five homogeneously sequenced light pulses or placebo treatment to both eyes, (E-Eye Intense Regulated Pulsed Light, E-Swin, France). Visual acuity, dry eye symptomology, tear film parameters, and ocular surface characteristics were assessed immediately before treatment on days 0, 15, 45, 75, and four weeks after treatment course completion on day 105. Inflammatory and goblet cell function marker expression, and eyelid swab microbiology cultures were evaluated at baseline and day 105.ResultsSignificant decreases in OSDI, SPEED, and SANDE symptomology scores, and meibomian gland capping, accompanied by increased tear film lipid layer thickness, and inhibited Corynebacterium macginleyi growth were observed in both treatment groups (all p < 0.05). Sustained clinical improvements occurred in both treatment groups from day 75, although significant changes from day 45, in lipid layer quality, meibomian gland capping, OSDI and SANDE symptomology, were limited to the five-flash group (all p < 0.05).ConclusionsIPL therapy effected significant improvements in dry eye symptomology, tear film lipid layer thickness, and meibomian gland capping in MGD patients. Five-flash IPL treatment showed superior clinical efficacy to four-flash, and an initial course of at least four treatments is suggested to allow for establishment of sustained cumulative therapeutic benefits prior to evaluation of overall treatment efficacy.Trial registration numberACTRN12616000667415.     

提高对睑板腺功能障碍的认识 重视睑板腺功能障碍相关性干眼的药物治疗

睑板腺功能障碍（MGD）是临床常见的眼表疾病,以睑板腺终末导管的阻塞和／或睑板腺分泌物质或量的改变为特征,导致脂质向泪膜的排出减少,引起泪液蒸发过强。睑缘和睑板腺的炎症是引起睑板腺阻塞,进而导致MGD的直接原因,可引起眼表功能的异常。MGD的诊断主要依靠临床症状与体征,其症状与干眼的症状相似,因此无诊断特异性。体征主要包括睑缘形态的变化、睑板腺分泌异常和睑板腺缺失。MGD的治疗方法包括热敷、清洁睑缘、促进睑板腺的分泌、抗菌、抗炎治疗及润滑眼表,中度、重度MGD患者可给予必要的抗炎治疗,常用的抗炎药物有糖皮质激素、非甾体类抗炎药及免疫抑制剂。临床医师在进行眼部疾病的检查时应重视睑板腺的功能状态,尤其在角膜屈光手术及内眼手术前更应重视MGD的筛查,以免术后引起严重的眼表并发症,有效规避医疗风险。     

前列腺素 E2含量与睑板腺功能障碍的相关性

目的：探讨泪液前列腺素E2含量与睑板腺功能障碍（ MGD）之间的关系。方法 MGD患者105例（210只眼）,采用放射免疫法测定泪液前列腺素E2含量,健康成年人34例（68只眼）设为对照。结果试验组泪液前列腺素E2含量平均（142．5±34．8）μg/L,较对照组（43．5±11．7）μg/L明显增高,差异具有显著统计学意义（ P ＜0．05）。结论 MGD患者泪液前列腺素E2含量增高。     

Prophylactic action of lipid and non-lipid tear supplements in adverse environmental conditions: A randomised crossover trial

PurposeTo evaluate the prophylactic benefits of lipid-based and non-lipid-based artificial tear lubricants, in dry eye disease, after adverse environmental exposure.MethodsTwenty-eight participants with dry eye disease were recruited in a prospective, double-masked, randomised crossover trial. On separate days, participants were randomised to receive a single application of a lipid-containing tear supplement (Systane Complete) to one eye, and a non-lipid containing eye drop (Systane Ultra) to the contralateral eye. Participants were then exposed to a previously validated simulated adverse environment. Symptoms, non-invasive tear film breakup time, lipid layer grade, and tear meniscus height were assessed at three time points; baseline, following eye drop instillation, and after exposure to the adverse environment.ResultsBoth treatments effected improvements in symptoms and non-invasive tear film stability following instillation (all p < 0.05), although an improvement in lipid layer quality was limited to the lipid-containing nano-emulsion tear supplement (p = 0.003). Although protective effects were conferred by both treatments following exposure to the simulated adverse environment, more favourable symptomology scores, non-invasive tear film stability, and lipid layer quality were observed in the lipid-containing tear supplement group (all p < 0.05). No significant changes were observed in tear meniscus height in both treatment groups (all p > 0.05).ConclusionsBoth the lipid and non-lipid-based artificial tear supplement demonstrated prophylactic benefits in a simulated adverse environment. However, the ability to preserve tear film quality and reduce dry eye symptomology was greater with the lipid-containing eye drop.Trial registration numberACTRN12619000361101     

Interactions of polar lipids with cholesteryl ester multilayers elucidate tear film lipid layer structure

PurposeThe tear film lipid layer (TFLL) covers the tear film, stabilizing it and providing a protective barrier against the environment. The TFLL is divided into polar and non-polar sublayers, but the interplay between lipid classes in these sublayers and the structure-function relationship of the TFLL remains poorly characterized. This study aims to provide insight into TFLL function by elucidating the interactions between polar and non-polar TFLL lipids at the molecular level.MethodsMixed films of polar O-acyl-ω-hydroxy fatty acids (OAHFA) or phospholipids and non-polar cholesteryl esters (CE) were used as a model of the TFLL. The organization of the films was studied by using a combination of Brewster angle and fluorescence microscopy in a Langmuir trough system. In addition, the evaporation resistance of the lipid films was evaluated.ResultsPhospholipids and OAHFAs induced the formation of a stable multilamellar CE film. The formation of this film was driven by the interdigitation of acyl chains between the monolayer of polar lipids and the CE multilayer lamellae. Surprisingly, the multilayer structure was destabilized by both low and high concentrations of polar lipids. In addition, the CE multilayer was no more effective in resisting the evaporation of water than a polar lipid monolayer.ConclusionsFormation of multilamellar films by major tear film lipids suggest that the TFLL may have a similar structure. Moreover, in contrast to the current understanding, polar TFLL lipids may not mainly act by stabilizing the non-polar TFLL sublayer, but through a direct evaporation resistant effect.     

Intense pulsed light treatment in meibomian gland dysfunction: A concise review

PurposeTo review the published literature related to application of intense pulsed light (IPL) for treating meibomian gland dysfunction (MGD).MethodsThe literature search included the PubMed database and used the keywords “Intense Pulsed Light and Meibomian Gland Dysfunction”.ResultsIPL is a new instrumental treatment modality for MGD. This treatment modality was originally developed for use in dermatology and was later adopted in ophthalmology for treating MGD. IPL therapy for MGD can improve tear film stability, meibomian gland functionality, as well as subjective feeling of ocular dryness. However, in the reviewed literature, there was great variability in patient selection, evaluation criteria, and treatment protocols and durations.ConclusionNumerous studies report that IPL is effective for treating MGD and a safe procedure. There is great potential for further improvements to the procedure, as large comparative studies employing different treatment modalities are lacking.     

Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease

PurposeTo evaluate the effects of meibomian gland dysfunction (MGD) and aqueous deficiency (AD) on friction-related disease (FRD).MethodsCross-sectional comparative study. This study included 550 eyes (550 patients) with dry eye disease (DED). The DED subtype and dynamic tear-film parameters by automated assessments were investigated for the analysis of FRD (superior limbic keratoconjunctivitis, conjunctivochalasis, and lid wiper epitheliopathy).ResultsPatients with FRD had a higher proportion of moderate-to-severe MGD and AD (p < 0.001 and p < 0.001, respectively). The dropout rate of the meibomian gland was higher (30.5 ± 31.8 and 14.1 ± 25.0%, p < 0.001), tear meniscus height (TMH) was lower (227.8 ± 60.4 and 241.7 ± 55.6 μm, p = 0.008), and he first non-invasive keratographic tear break-up time (NIKBUT-1) was shorter (5.9 ± 3.5 and 7.3 ± 3.7 s, p < 0.001) in patients with FRD than in those without FRD. In the logistic regression analysis with clinical manifestation, both moderate-to-severe MGD and AD were associated with FRD (odds ratios [OR] 12.27, 95% confidence interval [CI] 7.72–19.50, and 2.31, 95% CI 1.43–3.71], p < 0.001 and p < 0.001, respectively). The dropout rate was positively associated with FRD (OR 1.017, 95% CI 1.010–1.023, p < 0.001). TMH and NIKBUT-1 were negatively associated with FRD (OR 0.995, 95% CI 0.991–0.999, and 0.90, 95% CI 0.85–0.95, p = 0.039 and p < 0.001, respectively).ConclusionsThis study showed that FRD was highly associated with MGD and meibomian gland dropout rate, suggesting that FRD may be mainly affected by lipid components. AD and TMH also had a good but relatively lower association with FRD, compared to MGD and meibomian gland dropout rate.     

Association of meibomian gland architecture and body mass index in a pediatric population

PurposeTo determine if meibomian gland architecture in a pediatric population is impacted by body mass index (BMI).MethodsProspective evaluation of 175 eyes of 175 pediatric patients from two clinics. Demographic and clinical information were reviewed. Symptoms of dry eye were assessed with the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. Meibography was performed and grading of images was performed by a masked rater using a previously validated 5-point meiboscale (0–4) for gland atrophy and a 3-point score (0–2) for gland tortuosity.Results175 eyes of 175 participants aged 4–17 years (11.6 ± 3.7 years) were imaged. The mean meiboscore was 0.82 ± 0.94 (range 0–4) and the mean gland tortuosity score was 0.53 ± 0.70 (range 0–2). Ninety-six patients (56%) showed evidence of gland atrophy (meiboscore greater than 0) and the majority of patients (n=50, 29%) had a gland tortuosity score of 1. The mean BMI was 20.5 ± 4.86 kg/m² with 39.4% of patients (n = 69) above the 85th percentile. BMI percentile was not found to be a significant predictor of a meiboscore greater than 0 (odds ratio (OR) 1.004 95% confidence interval (CI) (0.99–1.10, p = 0.41). However, BMI percentile was found to be a significant predictor of gland tortuosity score (OR 1.01 95% CI (1.00–1.02), p = 0.02). Patients with BMI percentiles between 41 and 60 were 3.79 times more likely to have a gland tortuosity score of greater than 0 than patients with BMI percentiles between 0 and 20 (OR 3.789 CI (1.17–12.24)). No significant associations were found between age, race, or sex and meiboscore or tortuosity. There was a trend towards reduction in lipid layer thickness with increasing BMI percentile (p = 0.028, r² = 0.04).ConclusionIn this pediatric population, there was an association between meibomian gland tortuosity and higher percentiles of BMI. Future studies are needed to elucidate the pathogenesis of meibomian gland tortuosity and atrophy in pediatric patients.     

Impact of blinking on ocular surface and tear film parameters

Purpose

To investigate the influence of blinking on tear film parameters, ocular surface characteristics, and dry eye symptomology.

Alteration in meibum lipid composition and subjective symptoms due to aging and meibomian gland dysfunction

PurposeTo investigate the alteration in lipid composition of meibum, objective clinical signs, and subjective symptoms associated with aging and meibomian gland (MG) dysfunction (MGD).MethodsIn 10 MGD patients [4 males/6 females, mean age: 65.6 ± 7.9 years (range: 50–79 years)] and 24 healthy volunteer subjects [young subjects: 6 males/6 females, mean age: 25.7 ± 3.8 years (range: 20–35 years), elderly subjects: 6 males/6 females, mean age: 58.4 ± 7.5 years (range: 50–79 years)], three objective clinical signs were evaluated: MG orifice obstruction, meibum score, and tear film lipid layer interference pattern. Subjective symptoms were analyzed via a 15-item questionnaire. After careful collection of meibum samples, comprehensive lipid analysis was performed via liquid chromatography-mass spectrometry. Data was analyzed via JMP® ver. 13 (SAS Institute, Inc., Cary, NC) statistical analysis software.ResultsIn the MGD patients and elderly subjects, there was a significant decrease in non-polar lipids such as cholesterol esters (ChEs), while a significant increase in polar lipids [cholesterol (Ch), (O-acyl)-ω-hydroxy fatty acid (OAHFA), and free fatty acid (FA)] in total lipids (Tukey-Kramer test: p < 0.05). Triglyceride was significantly increased only in MGD patients (p < 0.05). Symptom scores representative of vision quality (i.e., blurred vision/haziness) were significantly negatively-correlated with the ratio of the non-polar lipid ChE, while significantly positively correlated with the polar lipids Ch, OAHFA, and FA (Spearman's rank correlation coefficient: p < 0.05).ConclusionsOur findings revealed that both MGD and aging affect the composition ratio of major meibum lipids, resulting in the appearance of subjective symptoms.     

Clinical evaluation of the efficacy and safety of heating physiotherapy goggles in the treatment of meibomian gland dysfunction

Objective: To evaluate the efficacy and safety of heating physiotherapy goggles in the treatment of meibomian gland dysfunction (MGD). Methods: A randomized controlled study was performed. Forty-four MGD patients were recruited in Wenzhou Medical University Eye Hospital from July 2021 to January 2022. Two patients were lost to follow-up. The patients were randomly divided into experimental group treated with heating physiotherapy goggles and control group treated with hot towels according to the random envelope method, with 21 patients (21 eyes) in each group. Throughout the study, the examiner was blinded. The data of the worse eye were analyzed. At baseline, 2 weeks and 4 weeks after treatment, the Ocular Surface Disease Index (OSDI), tear meniscus height (TMH), fluorescein breakup time (FBUT), corneal fluorescein staining score (CFS), lid margin hyperemia score and meibomian gland function scores were measured to evaluate the efficacy; visual acuity, intraocular pressure and slit lamp microscopy were examined to assess the safety. This study adhered to the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Wenzhou Medical University Eye Hospital (No. 2021-177-K-153-01). Results: There were significant differences in OSDI scores between before and after treatment (Ftime = 16.528, P<0.001). No significant difference was found in OSDI scores between 30.46 ± 17.31 at 2 weeks after treatment and 35.43 ± 18.22 before treatment in control group (P = 0.405). The OSDI score at 2 weeks after treatment was 26.27 ± 16.47, which was significantly lower than 39.24 ± 17.96 before treatment in experimental group (P = 0.001). The eyelid margin hyperemia score was 0.0 (1.0, 2.0) at 4 weeks after treatment in experimental group, which was significantly lower than 2.0 (1.0, 3.0) in control group (Wald χ2 = 11.444, P = 0.001). The morphologic scores of meibomian gland orifices at 2 and 4 weeks after treatment were both 1.0 (0.0, 1.0) in experimental group, which were significantly lower than 2.0 (1.0, 3.0) and 2.0 (1.0, 2.5) in control group (Wald χ2 = 15.082, 23.172; both at P<0.001). The scores of meibum quality at 2 and 4 weeks after treatment were 1.0 (0.5, 2.0) and 1.0 (0.0, 1.5) in experimental group, which were significantly lower than 2.0 (1.0, 2.0) and 2.0 (1.0, 2.5) in control group (Wald χ2 = 4.638, 9.395; both at P< 0.05). The scores of upper meibomian gland expressibility at 2 and 4 weeks after treatment were both 2.0 (1.0, 2.0) in experimental group, which were significantly lower than 3.0 (2.0, 3.0) and 2.0) 2.0, 2.5) in control group (Wald χ2 = 6.489, 11.562; both at P< 0.05). The score of lower meibomian gland expressibility at 4 weeks after treatment in experimental group was 1.0 (0.5, 2.0), which was significantly lower than 2.0 (2.0, 3.0) in control group (Wald χ2 = 24.085, P<0.001). The FBUT at 2 and 4 weeks after treatment were 3.00 (1.75, 3.50) and 3.00 (2.00, 4.00) seconds in experimental group, which were significantly longer than 1.00 (0.75, 2.00) and 2.00 (1.00, 3.00) seconds in control group (Wald χ2 = 8.576, 8.539; both at P<0.05). There were significant differences in TMH among different time points (Ftime = 8.874, P<0.001). In control group, the TMH at 4 weeks after treatment was (0.24 ± 0.09) mm, which was significantly higher than (0.18 ± 0.05) mm before treatment (P<0.05). In experimental group, the TMH at 4 weeks after treatment was (0.23 ± 0.09) mm, which was significantly higher than (0.17 ± 0.05) mm before treatment (P<0.05). Significant differences were found in CFS score among different time points (Wald χ2time = 10.116, p = 0.006). There was no statistically significant diferencs in CFS score between before and after treatment in control group experimental group, the CFS scores at 2 and 4 weeks after treatment were 0.0 (0.0, 1.5) and 0.0 (0.0, 0.0), which were significantly decreased in comparison with 0.00) 0.00, 4.00) before treatment (both at P<0.05). In experimental group, the visual acuiiy converted to the logarithm of the minimum angle of resolution at 2 and 4 weeks after treatment were 0.10 (0.00, 0.22) and 0.10) 0.00, 0.22), which was significantly better than 0.10 (0.00, 0.40) before treatment (both at P<0.05). There was no significant change in intraocular pressure at diferent time points between the two groups (Fgroup = 0.432, P = 0.515; Ftime = 0.329, P = 0.721). No serious adverse effects occurred in both groups during the follow-up period. Conclusions: Compared with hot towel therapy, the use of heating physiotherapy goggles can relieve ocular discomfort of MGD patients more rapidly and improve the function and status of the meibomian gland more significantly. Heating physiotherapy goggles can treat MGD safely and effectively. © 2023 Henan Institute of Ophthalmology. All rights reserved.     

阻塞型睑板腺功能障碍患者睑板腺的形态学观察

背景 阻塞型睑板腺功能障碍(OMGD)是睑板腺功能障碍的常见类型,目前认为OMGD是由于睑板腺导管的阻塞和/或睑脂分泌异常导致,因此睑板腺形态学的改变具有重要的临床意义. 目的 运用Keratograph 5M眼表综合分析仪观察OMGD患者睑板腺的形态学改变并对其进行分析. 方法 采用前瞻性病例观察研究方法.纳入2015年1-6月在天津医科大学眼科医院确诊的OMGD患者60例60眼,同时选择60名健康体检者作为正常对照组.分别对2个组受检者进行眼表疾病指数(OSDI)问卷调查、泪膜破裂时间(BUT)、Keratograph 5M眼表综合分析仪观察睑板腺缺失情况、睑板腺开口评分及睑脂评分.根据OSDI评分分为轻度OMGD组(12.0＜ OSDI≤22.0) 23例、中度OMGD组(22.0＜OSDI≤32.0)21例和重度OMGD组(32.0＜OSDI≤100.0) 16例.分别对3个组患者的睑板腺状况进行评估与分析. 结果 OMGD组OSDI评分、睑板腺缺失评分及睑脂评分均高于正常对照组,与正常对照组比较,差异均有统计学意义(Z=-9.425、-7.781、-8.954,均P＜0.05).OMGD组和正常对照组BUT分别为(6.10±1.91)s和(10.67±2.11)s,睑板腺开口评分分别为1.35±0.90和0.88 ±0.64,差异均有统计学意义(t=-12.418、3.276,均P＜0.05).轻度OMGD组、中度OMGD组和重度OMGD组间OSDI、睑板腺缺失评分及睑脂评分比较,差异均有统计学意义(H=52.121、37.180、13.642,均P＜0.05),BUT、睑板腺开口评分差异均有统计学意义(F=58.191、8.474,均P＜0.05).OSDI与睑板腺缺失评分、睑脂评分及睑板腺开口评分之间均呈正相关(r=0.708,P=0.000;r=0.759,P=0.000;r=0.270,P=0.003).BUT与睑板腺缺失评分、睑脂评分及睑板腺开口评分之间呈负相关(r=-0.692,P=0.000;r=-0.691,P=0.000;r=-0.192,P=0.036). 结论 Keratograph 5M眼表综合分析仪可以快速、精确地对睑板腺进行形态学观察.OMGD患者在眼表及睑板腺等方面与正常人存在差异.